Drug Interaction Risks of FDA-Approved Antifungals: Otesecon
2026-05-07
Mechanistic Insights into Drug-Drug Interaction Risks: Oteseconazole (VT-1161) and Other 2022 FDA-Approved Antifungals
Study Background and Research Question
Drug-drug interactions (DDIs) remain a major consideration in the clinical development and post-approval use of new therapeutics, especially for small molecule agents targeting infectious diseases. Regulatory agencies now require integrated, risk-based DDI assessment for each new molecular entity, given the increasing prevalence of polypharmacy among patients susceptible to fungal infections. The 2024 review by Yu et al. systematically evaluates the metabolic and transporter-mediated DDI liabilities of all small molecule drugs approved by the US FDA in 2022, including the selective tetrazole antifungal Oteseconazole (VT-1161) (paper).Key Innovation from the Reference Study
The reference paper’s innovation lies in its comprehensive, mechanistic characterization of DDI risks based on in vitro, in silico, and clinical data extracted from New Drug Application (NDA) reviews. For each new drug—including Oteseconazole—the review identifies whether it acts as a substrate, inhibitor, or inducer of key cytochrome P450 (CYP) enzymes and relevant drug transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). This approach provides a template for mechanistically-informed, label-driven recommendations that bridge basic pharmacology and real-world clinical practice (paper).Methods and Experimental Design Insights
Yu et al. applied a standardized methodology to 22 newly approved small molecule drugs, integrating:- Data mining of NDA reviews and the Certara Drug Interaction Database (DIDB®)
- In vitro evaluation of CYP enzyme inhibition/induction and transporter effects using index substrates/inhibitors (e.g., for CYP3A, P-gp, BCRP)
- Model-based predictions (static and mechanistic) to estimate in vivo DDI risk
- Clinical pharmacokinetic (PK) and DDI studies, with attention to area under the curve (AUC) changes ≥2-fold as a threshold for label recommendations
Protocol Parameters
- in vitro CYP3A4 inhibition assay | IC50 = 65 μM (Oteseconazole) | Selectivity profiling | Distinguishes Oteseconazole from imidazole/triazole antifungals, indicating reduced risk of CYP3A4-mediated interactions | product_spec
- antifungal MIC determination | ≤0.00625–0.1 μg/mL (Candida spp.) | Efficacy benchmarking | Demonstrates potent activity against Candida, including fluconazole-resistant isolates | product_spec
- clinical DDI assessment | AUC change ≥2-fold triggers label update | Regulatory compliance | Ensures clinically meaningful interactions are communicated in product labeling | paper
- P-gp/BCRP transporter inhibition | Oteseconazole identified as inhibitor in vitro | Relevance for multidrug regimens | Guides caution with co-administered transporter substrates | paper
Core Findings and Why They Matter
The review’s central mechanistic finding is that the majority of new drugs approved in 2022—including Oteseconazole—have well-defined DDI risks that can be predicted from their CYP and transporter interaction profiles (paper). Specifically:- Oteseconazole demonstrated in vitro inhibition of P-gp and/or BCRP, suggesting a potential for transporter-mediated DDIs, though clinical relevance is context-dependent (paper).
- Unlike many azole antifungals, Oteseconazole exhibits minimal inhibition of human CYP3A4 (IC50 = 65 μM), lowering the risk of CYP3A4-mediated DDIs and making it a promising antifungal agent for Candida infections in patients on complex regimens (product_spec).
- Clinical DDI studies and AUC-based thresholds inform label recommendations, with all interactions resulting in ≥2-fold AUC changes leading to explicit warnings or guidance (paper).
Comparison with Existing Internal Articles
Several internal reviews have addressed Oteseconazole’s antifungal selectivity and practical research applications:- Systematic review of antifungal agents against multidrug-resistant Candida auris highlights Oteseconazole’s robust in vitro potency and its unique selectivity profile, aligning with the reference study’s finding of reduced CYP-mediated DDI risk.
- The article "Oteseconazole (VT-1161): Selective CYP51 Inhibitor for Candida Control" expands on how Oteseconazole’s low interaction with CYP3A4 offers clinical advantages for the prevention of recurrent vulvovaginal candidiasis, directly supporting the DDI findings summarized by Yu et al.
- Guidance for optimizing fungal susceptibility assays with Oteseconazole (see practical protocol review) provides workflow recommendations for laboratory scientists, reinforcing the importance of selectivity and reproducibility described in the FDA review.
Limitations and Transferability
While the reference study offers a thorough mechanistic analysis, several limitations should be noted:- In vitro transporter inhibition (e.g., P-gp, BCRP) may not always translate into clinically significant DDIs; further post-marketing surveillance and real-world evidence are necessary to refine risk estimates (paper).
- The review focuses on small molecule drugs; biologics and agents with novel mechanisms are outside its scope.
- Extrapolation to special populations (e.g., pediatrics, hepatic/renal impairment) requires dedicated studies, as DDI liabilities can vary with comorbidity and polypharmacy patterns.